Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Ipsos/Axios survey; Note: ±3.2% margin of error for the total sample; Chart: Andrew Witherspoon/Axios

Fewer than 1 in 10 Americans have a great deal of trust in the Food and Drug Administration or pharmaceutical companies to look out for their interests, in the latest installment of the Axios-Ipsos Coronavirus Index.

Why it matters: This two-headed credibility crisis — over the medicine that's supposed to keep us safe and the regulators tasked with ensuring it does — shows how difficult it may be to get Americans to converge around a vaccine when the time comes.

  • This also underscores the dangers of politicizing government agencies tasked with administering science and protecting the public.

What they're saying: "It’s going to be hard for the authorities to communicate what people should be doing and how to be doing it," said pollster Chris Jackson, senior vice president for Ipsos Public Affairs.

  • "There’s going to be a huge organizational challenge in how do we get people pulling in the same direction — because nobody’s really trusted."

Between the lines: While both have their doubters, the FDA is the more trusted of the two for now.

  • 57% of Americans have some degree of trust in the FDA, though only 8% of those categorized it as a great deal of trust while the balance said they have a fair amount of trust.
  • Another 42% said they had either not very much trust in the FDA or none at all.
  • For pharmaceutical companies, the attitudes were flipped: 42% had some trust in the industry, though only 6% said they had a great deal of trust. Meanwhile, 57% said they had not very much or none at all.
  • Hispanic respondents have the most trust in both institutions; white respondents have the least.

By the numbers: More than half of respondents age 65 or older — but only one-third of adults under 30 — say they trust pharmaceutical companies.

  • Proximity to cities is a better predictor of skepticism about the FDA or pharmaceutical companies than party ID.
  • 60% of urban respondents and 57% in suburbs, but only 49% in rural areas, express trust in the FDA. When it comes to pharmaceutical companies, only one-third of rural residents express trust, 10 percentage points lower than for suburban or urban areas.

The big picture: Week 24 of our national survey reflects overall stability in U.S. attitudes toward the pandemic even as parents and school systems weigh how to return to class.

  • 35% of respondents with children under 18 say they've sent their kids back to in-person classes, while 54% have returned their kids to class via virtual or distance learning.
  • 64% of Americans say they feel about the same risk of contracting the virus as they did in April; 15% say they feel they're at greater risk, while 20% feel they're at lower risk.
  • About 9 in 10 respondents say they're wearing a mask and keeping a 6-foot distance from others.
  • 1 in 4 Americans have now been tested for the virus.
  • 6 in 10 know someone who's tested positive, and 23% know someone who's died.

Methodology: This Axios/Ipsos Poll was conducted Sept. 11–14 by Ipsos’ KnowledgePanel®. This poll is based on a nationally representative probability sample of 1,019 general population adults age 18 or older.

  • The margin of sampling error is ± 3.2 percentage points at the 95% confidence level.

Go deeper

Dec 23, 2020 - Health

Over 1 million people in U.S. have received the COVID-19 vaccine

Photo: Hyoung Chang/MediaNews Group/The Denver Post via Getty Images

More than 1 million people in the U.S. have received the first dose of the Pfizer-BioNTech coronavirus vaccine as of Wednesday, according to the Centers for Disease Control and Prevention.

Why it matters: The U.S. began its largest vaccination campaign in U.S. history last week as COVID-19 cases, hospitalizations and deaths surged nationwide.

Dec 23, 2020 - World

New York City will enforce quarantine for U.K. travelers with visits from sheriff's deputies

Mayor Bill de Blasio. Photo: Noam Galai/Getty Images

All U.K. travelers going to New York City will now be required to quarantine or face a daily $1,000 fine, Mayor Bill de Blasio announced on Wednesday.

Why it matters: Although all people are required to quarantine when traveling into the city, U.K travelers specifically will receive visits from sheriff’s deputies to ensure they are following the two-week quarantine order.